Compare NAVI & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAVI | NEO |
|---|---|---|
| Founded | 1973 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 1999 |
| Metric | NAVI | NEO |
|---|---|---|
| Price | $12.45 | $11.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $14.14 | $12.56 |
| AVG Volume (30 Days) | 860.5K | ★ 1.9M |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $443,000,000.00 | ★ $709,162,000.00 |
| Revenue This Year | N/A | $10.90 |
| Revenue Next Year | N/A | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.10 |
| 52 Week Low | $10.53 | $4.72 |
| 52 Week High | $16.07 | $19.12 |
| Indicator | NAVI | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 59.91 |
| Support Level | $12.24 | $11.66 |
| Resistance Level | $12.77 | $12.26 |
| Average True Range (ATR) | 0.38 | 0.50 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 79.93 | 68.83 |
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.